Print Data Published News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Print data published. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Print Data Published Today - Breaking & Trending Today

Bharat Biotech concludes Covaxin's final analysis; claims 77.8% efficacy in phase-3 trial

Bharat Biotech concludes Covaxin s final analysis; claims 77.8% efficacy in phase-3 trial
Sharing the final phase-3 pre-print data on medRxiv, Bharat Biotech claimed that Covaxin provides 65.2% protection against the Delta variant, which is currently the dominant COVID-19 strain in India
Bharat Biotech on Saturday announced that Covaxin has been found to be 77.8% effective against symptomatic COVID-19
BusinessToday.In
Updated Jul 03, 2021, 8:42 AM IST
Bharat Biotech said early on Saturday that it has concluded the final analysis for its COVID-19 vaccine Covaxin as part of phase-3 clinical trials.
Sharing the final phase-3 pre-print data on medRxiv, the Hyderabad-based pharma company claimed that its indigenous jab demonstrates an overall efficacy of 77.8% against symptomatic infection. ....

Andhra Pradesh , Bharat Biotech , Largest Efficacy , Print Data Published , ஆந்திரா பிரதேஷ் , பாரத் பயோடெக் ,

Coronavirus: Covaxin Overall 77.8% Effective, Claims Bharat Biotech In Final Phase 3 Data

Covaxin has received emergency use authorizations in 16 countries, Bharat Biotech said.
Highlights
The vaccine offers 65.2 per cent protection against Delta variant
Phase 3 trials were conducted on 130 symptomatic Covid patients
New Delhi:
Bharat Biotech s Covaxin is overall 77.8 per cent effective against Covid, the vaccine maker said today in a statement, citing the data from the third phase of clinical trials. The data, however, is yet to be peer-reviewed.
The vaccine offers 65.2 per cent protection , it said, against the rapidly emerging Delta variant.
It was also found to be 93.4 per cent effective against severe symptomatic COVID-19, the company said.
Covaxin is a whole virus inactivated vaccine against SARS-CoV2, developed by Bharat Biotech in partnership with ICMR and NIV Pune. ....

Andhra Pradesh , Bharat Biotech , Krishna Ella , Balram Bhargava , Suchitra Ella , Indian Council Of Medical Research , Department Of Health Research , Largest Efficacy , Print Data Published , Managing Director , Secretary Department , Health Research , Director General Indian Council , Medical Research , Genome Valley , Japanese Encephalitis , ஆந்திரா பிரதேஷ் , பாரத் பயோடெக் , கிருஷ்ணா எல்லா , பால்ராம் பார்கவா , சூச்சித்ர எல்லா , இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி , துறை ஆஃப் ஆரோக்கியம் ஆராய்ச்சி , நிர்வகித்தல் இயக்குனர் , செயலாளர் துறை , ஆரோக்கியம் ஆராய்ச்சி ,

Phase 3 trial: Covaxin 77.8% effective against symptomatic COVID-19, 65.2% against Delta Variant

Phase 3 trial: Covaxin 77.8% effective against symptomatic COVID-19, 65.2% against Delta Variant
The vaccine demonstrated 93.4% efficacy against severe symptomatic cases company said. The results are based on the evaluation of 130 confirmed cases.
(Image Source: Reuters)
Updated: Jul 3, 2021, 11:11 AM IST
Hyderabad-based Bharat biotech s Covaxin has been found to be 77.8% effective against symptomatic COVID-19 in its phase 3 clinical trials. It also showed 65.2% efficacy against the Delta Plus variant. The results are based on the evaluation of 130 confirmed cases.
The indigenously developed vaccine demonstrated 93.4% efficacy against severe symptomatic COVID-19, the company claimed.
The safety analysis demonstrated that adverse events reported post-vaccination were similar for Covaxin and the placebo. Twelve percent of subjects experienced commonly known side effects and less than 0.5% of subjects felt serious adverse ....

Bharat Biotech , Hyderabad Based Bharat , Delta Plus , Largest Efficacy , Print Data Published , பாரத் பயோடெக் , ஹைதராபாத் அடிப்படையிலானது பாரத் , டெல்டா ப்லஸ் ,